ASCENTAGE
LIVE

Serial Number

99113144

Owner

ASCENTAGE PHARMA (SUZHOU) CO., LTD.

Attorney

Kathryn E. Smith

Filing Date

Mar 31, 2025

Add to watchlist:

No watchlists yet
View on USPTO

ASCENTAGE Trademark

Serial Number: 99113144 • Registration: 8227611

ASCENTAGE is a trademark filed by ASCENTAGE PHARMA (SUZHOU) CO., LTD. on March 31, 2025. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

ASCENTAGE PHARMA (SUZHOU) CO., LTD. (23 trademarks)

68 XINQING ROAD
SUZHOU 215000 , CN

Entity Type: 03

Trademark Details

Filing Date

March 31, 2025

Registration Date

April 28, 2026

Published for Opposition

March 10, 2026

Goods & Services

Chemical preparations for medical purposes, namely, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs sold in bulk, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biochemical medicines for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; medicines for human purposes for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemico-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs for medical purposes in the nature of prescription apoptosis targeted compounds, next-generation kinase inhibitors and senolytic drugs; biological preparations for medical purposes, namely, biological preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemical preparations for pharmaceutical purposes, namely, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; radioactive substances for medical purposes; gases for medical purposes, namely, nitric oxide for medical purposes; chemical conductors for electrocardiograph electrodes; semen for artificial insemination; disinfectants; solutions for contact lenses; media for bacteriological cultures for medical purposes; medicated sweets; dietetic preparations adapted for medical purposes; depuratives for the body; diagnostic preparations for veterinary purposes; pesticides; sanitary napkins; cotton for medical purposes; dental abrasives; diapers for pets

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 28, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 28, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 10, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 10, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 4, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 12, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 11, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 11, 2026 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Feb 11, 2026 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 12, 2026 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 12, 2026 GNSL
SUSPENSION LETTER WRITTEN
Jan 12, 2026 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 5, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 5, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 5, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 10, 2025 GNRN
NON-FINAL ACTION E-MAILED
Sep 10, 2025 GNRT
NON-FINAL ACTION WRITTEN
Sep 10, 2025 CNRT
ASSIGNED TO EXAMINER
Aug 28, 2025 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Aug 14, 2025 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 14, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Mar 31, 2025 MAFR
NEW APPLICATION ENTERED
Mar 31, 2025 NWAP